Video Experimental Relacionado
Updated: Aug 11, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Los niveles plasmáticos de adenosina aumentan en pacientes con insuficiencia cardíaca crónica
1First Department of Medicine, Osaka University School of Medicine, Suita, Japan.
Circulation
|March 18, 1997
Resumen
Los niveles plasmáticos de adenosina están elevados en pacientes con insuficiencia cardíaca crónica, independientemente de la causa. Estos aumentos se correlacionan con la gravedad de la insuficiencia cardíaca, lo que sugiere un papel compensatorio para la adenosina.
Área de la Ciencia:
- Cardiología Cardiología.
- La bioquímica es la bioquímica.
Sus antecedentes:
- La adenosina es reconocida por sus efectos cardioprotectores.
- El papel de los niveles plasmáticos de adenosina en la insuficiencia cardíaca crónica sigue sin estar claro.
Objetivo del estudio:
- Para investigar los niveles plasmáticos de adenosina en pacientes con insuficiencia cardíaca crónica.
- Para determinar si los niveles de adenosina se correlacionan con la gravedad o la etiología de la insuficiencia cardíaca.
Principales métodos:
- Se analizaron 71 pacientes con insuficiencia cardíaca crónica.
- Los pacientes fueron categorizados por la causa de la insuficiencia cardíaca y la clase de la Asociación del Corazón de Nueva York.
- Los niveles plasmáticos de adenosina se compararon con 64 controles sanos.
Principales resultados:
- Los niveles plasmáticos de adenosina fueron significativamente más altos en pacientes con insuficiencia cardíaca isquémica (218 +/- 23 nmol/L) y no isquémica (211 +/- 21 nmol/L) en comparación con los controles (62 +/- 3 nmol/L).
- Los niveles elevados de adenosina se correlacionan con la gravedad de la insuficiencia cardíaca crónica.
Conclusiones:
- Los niveles sistémicos de adenosina en sangre aumentan en pacientes con insuficiencia cardíaca crónica.
- El aumento de la adenosina puede representar un mecanismo de compensación endógeno contra la lesión celular en la insuficiencia cardíaca.
Videos de Conceptos Relacionados
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.